TB-500: specifications, literature and price per milligram

What the TB-500 label actually refers to

TB-500 is a research designation applied to thymosin beta-4, an endogenous 43-amino-acid actin-sequestering peptide that carries the international nonproprietary name timbetasin. Some suppliers apply the same label to the much shorter actin-binding fragment instead.

Those are different molecules with different masses, and the distinction is not cosmetic when you are paying by the milligram. Full-length thymosin beta-4 has a molecular weight around 4963.4 g/mol and CAS 77591-33-4. A seven-residue fragment has a fraction of that mass and a fraction of the synthesis cost.

What the published literature examined

The published record is predominantly preclinical. Rodent dermal wound-repair models are among the earliest reports (Malinda et al., Journal of Investigative Dermatology 1999), with rodent corneal injury models examined subsequently.

Human evidence is largely confined to ophthalmic formulations of thymosin beta-4, which were evaluated in the randomised, placebo-controlled ARISE Phase 3 program in dry eye. Non-ophthalmic human evidence remains sparse. As with BPC-157, none of this is a claim about anything outside the model it was measured in.

Purity, identity and mass verification

Because the label is ambiguous, identity work carries more weight here than it does for a compound with only one plausible sequence.

• Mass spectrometry should resolve full-length versus fragment. Ask for the observed mass, not just a pass mark.
• HPLC purity as area percent with the chromatogram attached.
• Lot matching between the certificate and the vial in your hand.

A long peptide is harder to synthesise cleanly than a short one, which shows up as more closely-eluting related-substance peaks in the trace. That is normal chemistry, not a red flag, but it is a reason to want the chromatogram rather than the summary.

Price per milligram

TB-500 has historically carried a premium over BPC-157 at the boutique end of the market - our snapshot has one premium vendor at $19.00/mg against $14.40/mg for BPC. At volume the two converge, because the input that dominates cost at scale is synthesis throughput rather than sequence length.

Effect prices the 10mg vials identically: $39.99 list ($4.00/mg). The current price is visible on each product page.

Handling and storage of lyophilized material

Laboratory handling information only, for material in storage.

• Store the sealed lyophilized vial cold and dark on receipt.
• Aliquot rather than repeatedly freezing and thawing one vial.
• Longer peptides are not automatically less stable than short ones, but solution stability is sequence-specific and is shorter than powder stability in every case.

Why the name needs a specification

TB-500 is a market label, not a complete analytical description. A specification should state the intended sequence, whether the material is full-length thymosin beta-4, the expected molecular mass, the salt or counter-ion convention, the nominal vial mass and the acceptance criteria. Without those fields, two suppliers can use the same name for different materials.

Full-length thymosin beta-4 contains 43 residues. The shorter actin-binding fragments discussed in the literature contain only part of that sequence. A fragment is not a lower grade of the full-length material; it is a different analyte. Price, synthesis difficulty and expected mass all change with the identity.

This is why a catalog alias should never be allowed to become the reference standard. The reference standard must be the defined molecule. The label can then list TB-500 as an alias, but the test result should resolve what was actually measured.

What the early model paper measured

The 1999 paper by Malinda and colleagues used a full-thickness wound model in rats and also examined keratinocyte migration in a laboratory assay. The important reading habit is to keep those two experimental systems separate. A cell-migration assay is not an animal endpoint, and an animal endpoint is not a controlled human result.

The paper reported re-epithelialization, contraction, collagen deposition and angiogenesis under its study conditions. Those are measurements inside a defined rodent model. They explain why the peptide became a research subject; they do not authorize a claim for material sold on a catalog page.

The paper is also useful as a reminder that 'thymosin beta-4 research' covers more than one type of experiment. Later work includes cell assays, animal models and specialized ophthalmic development. Combining all of that into one undifferentiated evidence count would hide the route, formulation and endpoint differences.

Human ophthalmic work is a narrow evidence lane

Controlled human studies of thymosin beta-4 have concentrated on ophthalmic formulations. That is a formulation-specific development program with its own controls, manufacturing and regulatory record. It should not be used as a shortcut for claims about lyophilized research material or about other routes.

A useful literature table would therefore give the ophthalmic program its own row rather than placing it beside animal work as if the two were interchangeable. The columns should state population or model, formulation, comparator, primary endpoint, duration and publication status. That layout makes the narrowness of the human record visible without dismissing the work that does exist.

Reading a long-peptide chromatogram

Longer sequences create more opportunities for deletion products, incomplete coupling, oxidized material and closely eluting related substances. The main HPLC peak can still be dominant while smaller peaks carry useful process information. This is why the trace and integration table matter more than a rounded headline percentage.

A strong report lets a reader connect the peak table to the chromatogram and the identity result. Retention time alone does not prove identity. Mass alone does not describe the amount of related material. HPLC and mass spectrometry are complementary rather than competing tests.

For the full-length-versus-fragment question, the expected and observed mass are central. If a public summary omits the underlying report for commercial reasons, the vendor should still keep that comparison in its private release record and should never convert an ambiguous result into a stronger public claim.

Mass, purity and vial quantity

The labeled quantity, measured peptide content and HPLC area percent describe different properties. A 10mg label is a nominal quantity. A measured mass estimates how much target material was found under the chosen quantitative method. HPLC purity estimates the share of detected chromatographic area assigned to the principal component under that method.

Because those numbers have different denominators, they should not be multiplied together without understanding the method. A buyer should not infer measured mass from purity, and a vendor should not advertise an overfilled vial as though overfill were evidence of purity. Publish each result with its own label and precision.

A TB-500 procurement checklist

1. Define the full sequence and expected mass before requesting a quote.
2. Require the supplier and laboratory to use the same name for the same analyte.
3. Match the third-party sample identifier to the received batch before accepting the result.
4. Read the mass comparison before the purity percentage so a fragment cannot pass under an ambiguous name.
5. Keep the chromatogram, peak table and method with the private release record even if the public page exposes only a result summary.

The checklist is intentionally boring. Its purpose is to stop a naming problem from becoming an inventory problem.

Primary records used for this overview

• Malinda et al., 1999, rat full-thickness model and keratinocyte-migration assay: PubMed record.
• The molecular distinction on this page is tied to full-length thymosin beta-4 rather than to the TB-500 catalog nickname.

Sequence identity controls which literature belongs in the file

A full-length thymosin beta-4 paper does not automatically support a statement about a shorter actin-binding fragment. The fragment may retain a region discussed in a mechanism paper, but it does not retain every structural feature, interaction or experimental history of the parent sequence.

Build the literature file from the analyte outward. Put the sequence or defined form at the top, then include only papers that used that material or clearly identify a related material in a separate row. This avoids the circular practice of using an ambiguous catalog name to select the papers that are later used to define the name.

When a paper uses recombinant protein, synthetic peptide, a fragment, a formulation or a gene-expression model, record that distinction. Shared terminology does not make the interventions identical.

Formulation and route stay attached to the evidence

The ophthalmic development record is informative precisely because it is specific. Formulation, local exposure, study population, comparator and ocular endpoints are part of the intervention. Removing those details creates a broader statement than the study tested.

The same discipline applies to animal and cell work. A topical preparation in a model, a solution in culture and a lyophilized research vial are different experimental objects. A literature table should keep route and formulation beside the outcome rather than relegating them to a footnote.

This does not make the literature unusable. It makes it searchable by the question it can actually answer and stops evidence from one application being borrowed for another.

Setting acceptance criteria before the result arrives

A release decision is stronger when the criteria are written before testing. Define the intended sequence, acceptable identity comparison, purity method, quantity basis and lot-linkage requirement. If the report later falls outside a criterion, investigate rather than rewriting the criterion to fit.

For an alias-prone product, the identity criterion should be decisive. A high purity percentage on a fragment does not satisfy a specification for full-length thymosin beta-4. Likewise, a mass signal consistent with the target does not eliminate the need to inspect related chromatographic components.

Document the disposition: accepted, rejected, quarantined or requiring clarification. The result and the decision are separate records, and a later reviewer should be able to see both.

How to report uncertainty without losing the reader

A research summary can be plain spoken without presenting every uncertainty as a footnote. Start with the defined material and the measured endpoint, then state the model, comparator and largest limitation in the same paragraph. That structure gives the reader the finding and its boundary together.

For TB-500, the identity boundary comes first: full-length thymosin beta-4 and a fragment are not interchangeable. The evidence boundary comes next: cell, animal and ophthalmic records answer different questions. The analytical boundary is last: a historical sample does not certify later inventory.

This layered description is more useful than a confidence adjective. Words such as promising or strong can mean different things to different readers; sequence, design, replication and sample linkage are facts that can be checked.

Dates make that account auditable. Record when the literature search was run, when the price was observed and when the sample was tested. A reader can then tell whether an apparent conflict is a scientific disagreement or simply two records created at different times.